Table 3 The Undergoing clinicals trails of CRS management
From: Macrophage, the potential key mediator in CAR-T related CRS
NCT no | Trails | Status | Conditions | Inventions | Locations | Phase |
|---|---|---|---|---|---|---|
NCT04071366 | A study of itacitinib for the prevention of cytokine release syndrome induced by immune effector cell therapy | Not yet recruiting | Cytokine release syndrome | Drug: Itacitinib Drug: Immune effector cell therapy | Univ. of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States Moffitt Cancer Center, Tampa, Florida, United States Massachusetts General Hospital Boston, Massachusetts, United States (and 7 more…) | Phase 2 |
NCT03533101 | Tocilizumab for cytokine release syndrome prophylaxis in haploidentical transplantation | Unknown | Cytokine release syndrome stem cell transplant complications | Drug: Tocilizumab | Hospital Universitario Dr. Jose E Gonzalez UANL, Monterrey, Nuevo Leon, Mexico | Phase 1 Phase 2 |
NCT04048434 | Extracorporeal cytokine adsorption as additive treatment of CAR-T associated Cytokine Release Syndrome (CRS) | Not yet recruiting | Cytokine Release Syndrome CAR-T | Device: Cytosorb | Â | Not applicable |
NCT04082910 | Metoprolol for the treatment of cytokine release syndrome in patients treated with chimeric antigen receptor T cells | Recruiting | Solid tumor Hematologial malignancy | Drug: Metoprolol Drug: anti-TNFα antibody | Biotherapeutic Department of Chinese PLA General Hospital Beijing, Beijing, China | Phase 1 Phase 2 |
NCT04359784 | Anakinra for the prevention of cytokine release syndrome and neurotoxicity in patients with B-cell lymphoma receiving CD19-targeted CAR-T cell therapy | Not yet recruiting | B-cell non-hodgkin lymphoma | Biological: Anakinra Biological: Axicabtagene Ciloleucel | Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States | Phase 2 |
NCT03755414 | Study of itacitinib for the prophylaxis of graft-versus-host disease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation | Recruiting | Acute myelogenous leukemia Acute lymphocytic leukemia Myelodysplastic syndromes Non-hodgkin lymphoma Hodgkin disease | Procedure: Stem cell transplantation Drug: Itacitinib Other: Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Other: Human Activity Profile | Washington University School of Medicine, Saint Louis, Missouri, United States | Phase 1 |
NCT02906371 | Study of the tocilizumab optimization timing for CART19 associated cytokine release syndrome | Active, not recruiting | Lymphoblastic leukemia, acute, childhood | Drug: Tocilizumab Biological: CART 19 | Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States | Not Applicable |
NCT04048525 | Cytokine removal with CVVHD compared to CVVH | Completed | Cytokine release syndrome Sepsis AKI | Procedure: CVVHD Procedure: CVVH | Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain Hospital de la Santa Creu i Sant Pau, Barcelona, Spain | Not Applicable |
NCT02007239 | Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) | Active, not recruiting | Hemophagocytic lymphohistiocytosis | Drug: tocilizumab | Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States | Phase 2 |
NCT04148430 | A study of anakinra to prevent or treat severe side effects for patients receiving CAR-T cell therapy | Recruiting | B cell ALL B-cell lymphoma B-cell non hodgkin lymphoma | Drug: Anakinra | Memorial Sloan Kettering Cancer Center New York, New York, United States | Phase 2 |
NCT03275493 | Humanized CD19 CAR-T cells with CRS suppression technology for r/r CD19 + acute lymphoblastic leukemia | Recruiting | Acute lymphoblastic leukemia CD19 positive relapse refractory | Biological: Humanized CD19 CAR-T cells Biological: Humanized CD19 CAR-T cells with CRS suppression technology | The first affiliated hospital of soochow university Suzhou, Jiangsu, China | Phase 1 Phase 2 |
NCT04150913 | Anakinra in CAR-T cell mediated neurotoxicity | Not yet recruiting | Non hodgkin lymphoma Refractory non-hodgkin lymphoma Relapsed non hodgkin lymphoma Neurotoxicity Neurotoxicity syndromes cytokine release syndrome | Drug: Anakinra Drug: Axicabtagene Ciloleucel | Massachusetts General Hospital Boston, Massachusetts, United States Dana Farber Cancer Institute Boston, Massachusetts, United States | Phase 2 |